What's in Cape Fear Valley Health System's pipeline?

Cape Fear Valley Health System has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Cape Fear Valley Health System's portfolio?

Top competitors by shared drug class: Kavaklıdere Umut Hospital, ibrahim doğru.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/cape-fear-valley-health-system.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Cape Fear Valley Health System — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cape Fear Valley Health System pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Motrin and narcotic	Motrin and narcotic	marketed	NSAID + opioid analgesic combination	COX-1/COX-2 (ibuprofen); mu, delta, and kappa opioid receptors (narcotic component)	Pain Management

Therapeutic area mix

Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Kavaklıdere Umut Hospital · 1 shared drug class
ibrahim doğru · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cape Fear Valley Health System:

Cite this brief

Drug Landscape (2026). Cape Fear Valley Health System — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cape-fear-valley-health-system. Accessed 2026-05-17.